Participant flow

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 · Source last updated 2011-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Velcade 1.0 mg/m\^2 Velcade 1.3 mg/m\^2 D1,4, 8, 11 (x 6 cycles, then 1.0 mg/m\^2 (for cycles 7-12) Thalidomide 100 mg D1-28 Dexamethasone 20 mg D1-4 and 8-11

   id

   FG000

   title

   Velcade, Thalidomide, and Dexamethasone

2. description

   VMD: Velcade 1.3 mg/m\^2 D1, 4, 7, 10 (x6 mo, then 1.0 mg/m\^2) Melphalan 4 (6, 8, 10) mg/m\^2 D1, 4, 7, 10 dose escalation Dexamethasone 20 mg 1-4 and 7-10

   id

   FG001

   title

   VMD With Melphalan Dose Escalation

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         2

      type

      study stopped

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         2

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice